AS2676293 RANKL inhibitor RGNCY-0100
Per 10 mg
AS2676293 is a small molecule RANKL inhibitor that is effective in treating mouse metastasis in mouse models. AS2676293 is orally bioavailable and inhibited bone metastasis of human breast cancer cells (MDA-MB-231-5a-D-Luc2) and tumor-induced osteolysis. In transwell assays, AS2676293 inhibited bone metastasis of B16F10, a murine cell line that is known not to trigger osteoclast activation. AS2676293 has potential for development as a therapy for treating bone metastasis through the inhibition of both osteoclast bone resorption and tumor migration to bone.
Systematic Name: N-(4-fluoro-2-(trifluoromethyl)benzyl)-5-methoxy-2-(pyridin-2-yl)pyrimidin-4-amine
Mol Wt: 378.33
Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors. Miyata J. et al. Bioorganic & Medicinal Chemistry Letters 22 (2012) 5681–5684.
There are no uploaded files